← All trials
NCT02336542
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2014
- Primary completion
- Jul 1, 2015
- Completion date
- Jul 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 192
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Lead sponsor
- Fudan UniversityOverall official - principal investigator
- Tianjin UniversityOverall official - principal investigator
- Fudan UniversityCollaborator
- Proswell Medical CorporationCollaborator
- Tianjin UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.